Skip to main content
Pediatric brain tumors are the most common form of solid neoplasms in children and the most common cause of cancer death in children under age 14 in the United States (1, 2). Unfortunately, brain tumors usually do not have a pathognomonic clinical presentation. The initial presenting symptoms might mimic other more common conditions, such as migraine or gastroenteritis (3). This is particularly significant in younger patients for whom the neurological examination may be unreliable in identifying signs and symptoms revealing acute neurological decline. Symptoms may be subtle but could include headaches, lethargy, motor or sensory deficits, and signs of elevated intracranial pressure, such as nausea, vomiting, or visual disturbance.
Conventional wisdom is that pediatric brain tumors do not frequently present with psychiatric symptoms, such as mood swings or irritability. However, a recent review reported that behavioral and psychological symptoms were present in up to 57% of cases of CNS tumors among pediatric patients (4). These symptoms may include apathy, depression, mania, personality change, and eating disorders and may occur prior to the diagnosis or early during the clinical course of illness (5). Still, psychotic symptoms have not been commonly reported in the context of brain tumors, particularly in children.
Here, we present a case of this uncommon presentation: a brain tumor with associated psychotic symptoms in a school-aged child. An incidentally identified left-temporal lobe mass appeared to be associated with progressive psychosis and mood disorder symptoms. Despite aggressive pharmacologic treatment, psychiatric symptoms progressed. After several years of clinical observation, the psychiatric symptoms proved refractory to medications. Although radiologic progression had not clearly occurred, the decision was made to perform surgical resection of the mass, which was identified as a grade II ependymoma, and the child’s psychotic symptoms rapidly abated postoperatively.

Case Report

A pediatric patient initially presented at age 6 with a long-standing history of difficult-to-treat gastroesophageal reflux disease with aspiration as well as moderately persistent asthma. Prior to a planned Nissen fundoplication, the patient underwent brain imaging to rule out intracranial lesions associated with persistent nausea and reflux. MRI revealed a left-temporal heterogeneously enhancing mass (2.2×1.6×1.3 cm), with little surrounding edema or mass effect. At this juncture, given the lack of neurological clinical findings and the low likelihood of the mass contributing to her gastrointestinal symptoms, the decision was made to conduct clinical follow-up with serial, repeated MRI. Her gastrointestinal symptoms continued to be managed medically.
Initial examination revealed a healthy appearing, well-nourished, well-developed right-handed female in no acute distress. The child was without developmental delay and had full range and stable affect. No focal motor or sensory deficits were found on neurological examination. Her reflexes were brisk and symmetric. No seizure activity was identified, and other medical history and review of systems were unremarkable, except for presenting symptoms and mild asthma. Regarding the mass, the patient was followed clinically and with serial MRI over a 3-year period. Although the mass size slightly fluctuated (actually getting smaller in the transverse dimension, 2.2×1.8×1.5 cm), the patient did not show signs of disease progression (Figure 1). Spinal imaging was negative for the presence of metastases.
FIGURE 1. Neuroimaging findings in a school-aged child with a tumor associated with psychotic symptomsa
a Panel A shows axial fluid-attenuated inversion recovery MRI sequences revealing a left-temporal lobe tumor adjacent to the left-temporal horn, with minimal mass effect or surrounding edema (white arrowhead) at the time of diagnosis. Panel B shows a follow-up MRI scan, conducted 3 years after the initial scan, revealing slightly decreased tumor size. Panel C shows the postoperative MRI scan, revealing gross total resection with residual fluid-filled cavity (white star).
Shortly after initial presentation, therapy with a psychotherapist was initiated for mild anxiety and behavioral concerns. The child experienced brief, intermittent crying spells and had one instance of suicidal ideation associated with a social stressor. Mood concerns were successfully reduced through implementation of parent-management training strategies; however, the family continued ongoing psychotherapy to closely monitor symptoms. Approximately 1.5 years after the initial identification of the mass, the patient had a recurrence of depressed mood, vague suicidal ideation, and gradually increasing auditory and visual hallucinations. A complete neurological work-up did not reveal causation for changes in symptoms. Three routine EEGs were negative for epileptiform findings; however, intermittent slow activity maximal over the left-temporal lobe was noted.
Over the next year, the child had a worsening course that required three visits to the emergency department, a brief hospital stay, and more intensive outpatient psychiatric treatment. Her symptoms included worsening anxiety bordering on panic attacks, intermittent depressed mood, suicidal ideation, and continued auditory and visual hallucinations. The auditory hallucinations were unrelated to mood at times and included prominent experiences of the “devil” communicating with her and telling her to harm herself or others, although she could resist the hallucinations, because “she knew what it was.”
She was considered to have a primary mood disorder and was treated with escitalopram to target depressive and anxiety symptoms. Additionally, aripiprazole was later added to address her intrusive auditory hallucinations. Aripiprazole, at a dosage of 5 mg daily, was initially effective in reducing the hallucinations, but the efficacy gradually waned despite dose adjustments. In addition, the patient experienced significant side effects, including a 23-kg weight gain over a 2-year time period (increasing weight from the 75th percentile to the 98th percentile). The severe obesity worsened her underlying asthma and gastrointestinal symptoms. She continued psychotherapy concurrent with her psychiatric treatment but worsened academically and socially and gradually became more isolated from her family, with limited activities beyond engaging in media consumption. After extensive consultation with the psychiatric, oncologic, and neurosurgical teams, the decision was made to remove the tumor surgically, because it was considered to be a potential etiology for the psychosis and mood disorder.
Under general anesthesia, a standard temporal craniotomy was performed with image guidance. The patient’s brain was not found to be edematous. A medial temporal gyrus corticectomy was performed. The tumor was tough in consistency and mostly avascular. The mass abutted against the lateral ventricle and head of the hippocampus and was connected vascularly from the choroid plexus in the lateral ventricle on the superior aspect of the temporal horn. On the medial surface, it appeared that the tumor was attached to the ependymal surface overlying the head of the hippocampus. Through the resection process, the ependymal surface of the hippocampal head was uncovered to the extent that the gray matter within was well visualized, although there was still white matter border surrounding the tumor resection cavity. Intraoperatively, it was apparent that the amount of neoplastic tissue was more significant than initially appreciated by radiographic findings. Gross total resection was achieved.
Histopathologic examination revealed a low-grade tumor compatible with ependymoma (grade II, using the World Health Organization tumor grading system), with a Ki67 proliferation index <1%. Immunohistochemical staining demonstrated GFAP and EMA expression in neoplastic cells. Schistosoma mansoni proteases SM31 immunostaining showed no significant infiltration by neoplastic cells (Figure 2). P53, OLIG2, and mutant IDH1 proteins were negative.
FIGURE 2. Histological evaluation of a school-aged child with a tumor associated with psychotic symptomsa
a Histological evaluation of tumor tissue revealed a low-grade (grade II, in accordance with the World Health Organization tumor grading system) ependymoma with low mitotic index and no anaplastic features. Hematoxylin and eosin histologic sections from the central compact tumor show characteristic perivascular pseudorosettes (panel A, scale=50 microns) and lumen containing true rosettes (panel B, scale=50 microns). Hematoxylin and eosin staining shows the well-defined border of the tumor with adjacent brain parenchyma (panel C, scale=100 microns). Glial fibrillary acidic protein immunostaining demonstrates the glial nature of the neoplasm (panel D, scale=50 microns). Epithelial membrane antigen immunostaining shows intracytoplasmic microlumina (arrowheads) in tumor cells (panel E, scale=50 microns). SM-31 neurofilament immunostaining shows the sharp interface with the surrounding brain parenchyma (panel F, scale=100 microns).
The immediate postoperative course was uneventful, and the patient’s neurological examination was unchanged. In addition, her ophthalmologic and audiologic examinations were normal. She continued outpatient psychiatric treatment following the resection of her tumor. Over the next year, the child’s mood and anxiety symptoms significantly improved, and there were no further instances of hallucinations or suicidal or homicidal ideations. Neuropsychological testing was completed 3 months after surgery and indicated a decline of 18 points in her full-scale IQ and possibly worsened memory function. Despite these difficulties, she returned to school full-time, with satisfactory academic achievement. Two years following her surgery, the patient remained free from hallucinations, was tapered off all of her psychiatric medications, lost weight, and had no evidence of recurrence on MRI.

Discussion

Ependymoma is the third most common brain tumor in children after medulloblastoma and astrocytoma. Factors such as increasing age, spinal location, and gross-total resection are reported to be associated with improved survival (6). Recent studies have identified nine molecular groups of ependymoma, three from each principal anatomical location of the neuraxis, including the supratentorial, posterior fossa, and spinal compartments (7). Molecular classification of ependymoma will likely play a major role in the stratification of patients for adjuvant therapy. Although the existing literature suggests that it may be unusual with pediatric patients to expect psychotic symptoms to result from a brain tumor, the above case suggests otherwise. Specific tumors are not consistently associated with specific psychiatric symptoms; however, some cases suggest that the location of the tumor may play a role. Kugaya et al. (8) reported a case of ependymal cyst resection from the posterior aspect of the left-lateral ventricle, which led to resolution of depressed mood, depersonalization, and suicidal ideation in the patient.
In the above case, the discordance between the radiographic and clinical findings was remarkable, even though there was some uncertainty about specific connectivity or physiology that could explain the patient’s symptoms. However, the tumor itself abutted against the hippocampus and was likely to have caused mass effect, albeit subtle. The resection process itself required significant exposure of the hippocampal head. Extension of the tumor disrupting the integrity of the hippocampal space could plausibly be expected to affect function, if not by mass effect, then perhaps by altering physiologic stability. Electrographically, even though epileptiform findings were not present, slowing was intermittent and prominent over the left-temporal lobe, also suggesting a focal cerebral disturbance.
Ultimately, this case strongly implicates the temporal lobe as relevant in symptoms of depression as well as hallucinations. The temporal lobe’s role in long-term memory is also implicated in this case and may represent an example of potentially negative consequences of surgical resection in this location (2, 9). Neural circuitry involving the temporal lobe is known to play a role in affective disorders and is also suspected in psychosis (10, 11). Any type of pathology affecting the temporal lobe may then be intuitively expected to have an effect on such psychiatric symptoms. In pediatrics, mood disorders appear to be more common for seizure localization in the temporal lobe, especially if the seizures are refractory to medical treatment (12, 13).
Whether this case reflects unique roles of the tumor or the role of the location of the tumor is difficult to establish. Primarily, this case highlights the challenging aspects of managing young patients who have suspected tumors that are incidentally diagnosed. Although a CNS mass uncommonly underlies newly presenting psychiatric symptoms among children, in our patient, psychiatric symptoms were notably refractory to pharmacologic and psychotherapeutic interventions. This ultimately compelled the treatment team to pursue surgery despite apparently stable MRI. Although still speculative, the fact that the tumor progressed well beyond what could be identified radiographically suggests that the psychiatric symptoms likely resulted from the tumor effect.
Our patient’s rapid postoperative improvement perhaps even more convincingly demonstrated that the tumor was the etiology of her symptoms. Despite memory problems, her overall outcome has positively affected her quality of life and that of her family. This case highlights the importance of keeping brain tumors on the differential diagnosis for children who present with new psychiatric symptoms, especially psychotic symptoms, which can be associated with temporal lobe involvement. Additionally, it is one of the few cases in the pediatric literature, to our knowledge, to directly demonstrate that surgical management to remove a previously unrecognized brain tumor may be a successful treatment for serious medically refractory psychiatric symptoms.

Footnotes

The authors have confirmed that details of the case have been disguised to protect patient privacy.
The authors report no financial relationships with commercial interests.

References

1.
Ostrom QT, de Blank PM, Kruchko C, et al: Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2015; 16(suppl 10):x1–x36
2.
Sands S, Van Gorp WG, Finlay JL: A dramatic loss of non-verbal intelligence following a right parietal ependymoma: brief case report. Psychooncology 2000; 9:259–266
3.
Amid A, Keene DL, Johnston DL: Presentation of central nervous system tumors, in Pediatric Neuro-Oncology. Edited by Sheinemman K, Bouffet E. New York, Springer, 2005, pp 3–7
4.
Zyrianova Y, Alexander L, Faruqui R: Neuropsychiatric presentations and outcomes in children and adolescents with primary brain tumours: systematic review. Brain Inj 2016; 30:1–9
5.
Madhusoodanan S, Ting MB, Farah T, et al: Psychiatric aspects of brain tumors: a review. World J Psychiatry 2015; 5:273–285
6.
Andreiuolo F, Ferreira C, Puget S, et al: Current and evolving knowledge of prognostic factors for pediatric ependymomas. Future Oncol 2013; 9:183–191
7.
Pajtler KW, Witt H, Sill M, et al: Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015; 27:728–743
8.
Kugaya A, Fujikawa T, Yoshimura Y, et al: Ependymal cyst and psychiatric symptoms. J Neurol Neurosurg Psychiatry 1996; 60:461–462
9.
Charalambides C, Dinopoulos A, Sgouros S: Neuropsychological sequelae and quality of life following treatment of posterior fossa ependymomas in children. Childs Nerv Syst 2009; 25:1313–1320
10.
Roalf DR, Quarmley M, Calkins ME, et al: Temporal lobe volume decrements in psychosis spectrum youths. Schizophr Bull 2017; 43:601–610
11.
Drevets WC, Price JL, Furey ML: Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008; 213:93–118
12.
Salpekar JA, Berl MM, Havens K, et al: Psychiatric symptoms in children prior to epilepsy surgery differ according to suspected seizure focus. Epilepsia 2013; 54:1074–1082
13.
Salpekar JA, Mishra G, Hauptman AJ: Key issues in addressing the comorbidity of depression and pediatric epilepsy. Epilepsy Behav 2015; 46:12–18

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 305 - 308
PubMed: 31795806

History

Received: 2 July 2019
Revision received: 6 September 2019
Accepted: 23 September 2019
Published online: 4 December 2019
Published in print: Summer 2020

Keywords

  1. CNS Tumors
  2. Psychosis
  3. Mood
  4. Pediatrics
  5. Childhood Neuropsychiatric Disorders

Authors

Details

Nadimire Jules-Dole, M.D.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
Rafael Uribe-Cardenas, M.D., M.H.S.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
Lisa J. McReynolds, M.D., Ph.D.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
Lindsay Borden, Ph.D.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
Shawn Chambers, M.D.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
W. Robert Bell, M.D.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
Edward S. Ahn, M.D.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
Eric Raabe, M.D., Ph.D.
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).
Jay A. Salpekar, M.D. [email protected]
The Departments of Psychiatry (Jules-Dole, Borden, Chambers, Salpekar), Neurosurgery (Uribe-Cardenas), Pathology (Bell, Raabe), and Neurology (Salpekar) and the Division of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (McReynolds, Raabe), Johns Hopkins University School of Medicine, Baltimore; the Department of Neurological Surgery, Cornell University, New York (Uribe-Cardenas); the Department of Neurologic Surgery, Mayo Clinic, Rochester Minn. (Ahn); and the Kennedy Krieger Institute, Baltimore (Salpekar).

Notes

Send correspondence to Dr. Salpekar ([email protected]).

Competing Interests

Dr. McReynolds is currently a U.S. government employee; this study was conducted while she was employed by Johns Hopkins University.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share